Clinical Trial Update: Anti-PD-L1 and SAbR for Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of anti-PD-L1 therapy with SAbR (stereotactic ablative radiotherapy) in recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer; ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• Anti-PD-L1 (PD-L1 inhibitor)
• SABR

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Recurrent Epithelial Cancer of Ovary, Primary Peritoneal Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2020-11-12